Welcome to UK420

Register now to gain access to all of our features. Once registered and logged in, you will be able to contribute to this site by submitting your own content or replying to existing content. You'll be able to customize your profile, receive reputation points as a reward for submitting content, while also communicating with other members via your own private inbox, plus much more!

This message will be removed once you have signed in.


Search the Community: Showing results for tags 'health'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Welcome to UK420
    • New Members
  • Cultivation
    • Strain Base
    • Breeders Help Desks
    • Compost and Pots
    • Hydroponics
    • Outdoor Growing
    • Propagation, Cloning and Mother Plants
    • Auto Flowering
    • Growroom Design
    • Problem Solver
    • Harvesting and Processing
    • Grow Diaries
    • Cream Of The Crop
  • Cannabis Culture
    • News, Views and Politics
    • Medicinal Cannabis
    • Smokers Lounge
    • Uk420 Competitions
  • Sponsor Support
    • One Tree Horticulture
    • Intense Nutrients
    • Ledgrowlights.co.uk (diyleduk)
    • Vapefiend - The Vaporizer Specialists

Calendars

  • Community Calendar

Found 65 results

  1. hi Why are there age restrictions on CBD products? Whether its for toys, movies or alcohol, the end goal for regulations on every product category is the same – safeguarding consumers from potential harm. The same holds true for the marijuana industry as well where age restrictions and other directives are imposed on all cannabis off-shoots, including CBD for consumer welfare. Although some might find the age restrictions on CBD products as being too conservative, but it is a fact that the marijuana industry is still in its infancy. This means that researches revealing the true impact of the drug on the mind and body, whether positive or negative, are very limited. Unfortunately, a majority of what researchers have strived to know to this day are very recent developments. These can be proved inaccurate at any point in time by further researches, setting new paradigms for analysts. Federal prohibition of the drug has wasted about 80 years of knowledge that could have been fruitful today and helped in a better understanding of its behavior. Therefore, age restrictions on CBD and other cannabis derivatives are deemed necessary to stop any possible negative impacts from affecting individuals, specially the youth. According to many studies, the negative impacts of drugs or alcohol are amplified exposure is at a younger age. Why is the Marijuana industry moderated with age restrictions? Looking at the behavior of other industries like tobacco and alcohol, the legal age for consuming their products is 21+. Surely, this benchmark is not a random selection and has a scientific explanation behind it. The age limit of 21 years is applied because below this age, these substances can interfere with the brain development of young adults. This can negatively impacting their cognitive responses and capability of emotional regulation. The repercussions can be serious for the individual as well as anyone who comes into contact with them. From cases of driving under the influence to a decline in workplace productivity, exposure to marijuana and it’s derivatives at an early age can be damaging to individuals as well as society as a whole. Are all derivatives of cannabis equally addictive? Both hemp and marijuana are offshoots of the cannabis strain of plants and are a rich source of CBD. Their major difference is their THC content. THC is a compound that is primarily responsible for the psychoactive effects associated with marijuana. It causes users to feel high when consumed. While CBD is free from psychoactive effects, some products might carry trace amounts of THC in them. Hemp derived CBD contains less than 0.3% of THC, and that derived from marijuana contains a higher concentration of THC. Due to its lower THC concentration, hemp derived CBD was removed from the Schedule 1 classification. Later it was legalized in all 50 states. However, in an attempt to give users the ‘entourage effect’ a lot of CBD products contain THC. A study conducted in 2010 found that a combination of THC and CBD was more effective in relieving symptoms of cancer patients than a THC and placebo combination. When consuming products that contain a higher level of THC, users can possibly experience withdrawal symptoms in cases of overuse. Even though many researches have proven that overdosing on CBD is an impossibility, but addiction, cognition difficulties and dependence that come with other ingredients used in it are also factual realities. Despite of its low potential of addiction and abuse, CBD is not a completely side-effect free product. Minor side-effects like drowsiness, fatigue, and dry mouth have been reported. In addition to this, the possibility of drug interactions with CBD can become a huge health risk. According to a study conducted in 1993, CBD blocked an enzyme that was responsible for eliminating drugs from the system. This could result in a toxic buildup of pharmaceutical chemicals in the body, leading to serious consequences. Are age restrictions on CBD justified? Considering the possibility of side-effects that may result with using CBD products, age restrictions are quite rightly justified. Most teenager are itching to explore their newfound freedom and might end up getting themselves in harms way. The legal age of 21 assures that individuals are past the excitement phase and will make sensible decisions. In addition, age restrictions also assure that the mental development of individuals is not affected with an early exposure. Related Topics: A graduate in Bachelors of Business Administration, Yumna Haq is an ardent researcher and a dedicated writer. Having lived in three different counties, her cultural exposure is vast, allowing her to reflect more knowledge in her work. She's currently working for Cannabis Health Insider as a news writer. https://cannabishealthinsider.com/5550/why-are-there-age-restrictions-on-cbd-products/ Bongme
  2. hi How To Fight Depression And Anxiety With Medical Cannabis And CBD According to the Anxiety and Depression Association of America, anxiety affects more than 40 million adults in the U.S., which reflects up to 18.1 percent of the population annually. Even though this mental illness is manageable, only 36.9 percent of the victims seek treatment. Anxiety and depression are closely related. If you have anxiety, then the chances are high that you are depressed, and the reverse is also true. Coping with these disorders is not easy. They reveal symptoms like racing thoughts, pain, reduced energy, anger, loss of appetite, and more. All of these can affect your work and relationships in different ways. They can get worse when left untreated. You may be wondering what cannabis has to do with fighting depression and anxiety. Well, cannabis use for these conditions dates back to several years. Fast forward to today, many scientific studies now suggest that cannabis can help. Even better, CBD, a compound of cannabis, can treat these mental issues and has no psychoactive effects. What Does Research on Cannabis and CBD Say? More than 30 U.S. states have legalized cannabis for medicinal use and are considering it for recreational use. More people are also turning to cannabis for treating mental illnesses. While there are still limited studies, new scientific studies and anecdotal reports suggest cannabis may help relieve the symptoms of depression and anxiety. Studies reveal that growing trusted marijuana seeds in US indoors as a treatment for numerous health problems like anxiety and depression is increasing. The preclinical studies show its potential in managing these conditions. The research also suggests that CBD and THC enhance the endocannabinoid system, which regulates most body functions. So, can cannabis and CBD improve the symptoms of anxiety and depression? Let’s look at how they can help. How Medical Cannabis and CBD Help in Treating Depression and Anxiety Improves Sleep Sleep problems are common issues with depression and anxiety. However, the relationship between the two is a little complex. While the lack of sufficient sleep can trigger these conditions, depression and anxiety can also disrupt sleep patterns. High-quality medical cannabis from reputed cannabis online Canada dispensaries can help fight insomnia and other sleep problems. Its use as a sleep aid goes back thousands of years. Much of the sleep-inducing effects is owed to cannabis’s sedative and relaxing effects. Generally, marijuana allows you to fall asleep faster. This feature was revealed in a study that concluded that cannabis reduces the time it takes to fall asleep. The participants in the study included people with sleep issues and those without them. As a result, those with sleep issues showed an improvement in falling asleep by up to 30 minutes and an average of 15 minutes for those with no sleep problems. This study agrees with other research suggesting that cannabis reduces the time needed to fall asleep, decreases REM sleep, and increases slow-wave sleep. These effects are associated with cannabis’ THC compound. However, cannabis works in different ways to provide better sleep and ease conditions like anxiety and depression. That’s because of the different effects caused by THC and CBD. A study found that taking cannabis strains with high levels of THC is more effective in reducing REM sleep. It helps decrease dreams and nightmares, especially in PTSD patients. Other research shows that CBD vape juice to help you sleep and ease anxiety. In fact, researchers investigated the effects of taking CBD daily on two groups with poor sleep and anxiety. They found a reduction of anxiety levels by 79.2 percent and improved sleep by 66.7 percent. Treats Chronic Stress Prolonged stressful situations can lead to depression and worsen anxiety. Researchers have looked into the role of stressful life events in the development of depression, and the findings support this claim. New research by the University of Buffalo discovered that the endocannabinoid chemicals in the brain work the same way as the cannabinoids found in cannabis. The effect of the interaction results in an improved mood, which can ease depression and anxiety. The experiments on rats revealed that the brain produces fewer endocannabinoids when you’re suffering from chronic stress. Introducing cannabinoids from cannabis helps restore the normal levels of endocannabinoids and consequently fight the symptoms of depression. CBD is also becoming the go-to treatment for chronic stress. It works by reducing your body’s sensitivity to stress and possibly eliminating the severe effects of anxiety and depression. CBD does this in different ways: CBD Promotes Brain function As you get nervous, the sensitivity of the hypothalamus to cortisol drops. That means you need higher cortisol levels to get normal responses, and lack of it prolongs stress. CBD improves the hypothalamus’ sensitivity to cortisol, thus helping to stop stress immediately. Protects your Body from Destruction by Stress Stress causes damage to your body through oxidative stress. It’s a condition that leads to the accumulation of free radicals causing damage to the body and reduces its detoxification ability. CBD is a powerful antioxidant. Introducing it to the body helps counter the free radicals, thus protecting your body from damage. CBD for Rest & Digest When the body detects a problem, it increases the release of hormones such as cortisol and norepinephrine in the brain. These prepare the body to fight off stressful situations by increasing brain activity. But there’s a challenge caused by the opposing effects of gamma-aminobutyric acid (GABA) hormones that reduce and inhibit the activity of neurons and nerve cells. In one study, researchers introduced cannabidiols that blocked GABA in animals. This triggered them to experience hyperactive seizures. The research concluded that CBD effectively inhibited GABA effects and can be used to ease anxiety by increasing relaxation. Another study also shows that CBD can help ease anxiety in patients with a generalized social anxiety disorder (SAD). This condition is a common form of anxiety that impacts one’s social life. The study revealed that CBD helped ease the state and altered the brain’s response to this anxiety. https://marylandreporter.com/2020/10/20/how-to-fight-depression-and-anxiety-with-medical-cannabis-and-cbd/ Bongme
  3. hi Cannabis reduces OCD symptoms by half in the short-term, finds study The researchers analysed data inputted into the Strainprint app by people who self-identified as having OCD, a condition characterised by intrusive, persistent thoughts and repetitive behaviours such as compulsively checking if a door is locked. After smoking cannabis, users with OCD reported it reduced their compulsions by 60%, intrusions, or unwanted thoughts, by 49% and anxiety by 52%. The study, recently published in the Journal of Affective Disorders, also found that higher doses and cannabis with higher concentrations of CBD, or cannabidiol, were associated with larger reductions in compulsions. "The results overall indicate that cannabis may have some beneficial short-term but not really long-term effects on obsessive-compulsive disorder," said Carrie Cuttler, the study's corresponding author and WSU assistant professor of psychology. "To me, the CBD findings are really promising because it is not intoxicating. This is an area of research that would really benefit from clinical trials looking at changes in compulsions, intrusions and anxiety with pure CBD." The WSU study drew from data of more than 1,800 cannabis sessions that 87 individuals logged into the Strainprint app over 31 months. The long time period allowed the researchers to assess whether users developed tolerance to cannabis, but those effects were mixed. As people continued to use cannabis, the associated reductions in intrusions became slightly smaller suggesting they were building tolerance, but the relationship between cannabis and reductions in compulsions and anxiety remained fairly constant. Traditional treatments for obsessive-compulsive disorder include exposure and response prevention therapy where people's irrational thoughts around their behaviours are directly challenged, and prescribing antidepressants called serotonin reuptake inhibitors to reduce symptoms. While these treatments have positive effects for many patients, they do not cure the disorder nor do they work well for every person with OCD. "We're trying to build knowledge about the relationship of cannabis use and OCD because it's an area that is really understudied," said Dakota Mauzay, a doctoral student in Cuttler's lab and first author on the paper. Aside from their own research, the researchers found only one other human study on the topic a small clinical trial with 12 participants that revealed that there were reductions in OCD symptoms after cannabis use, but these were not much larger than the reductions associated with the placebo. The WSU researchers noted that one of the limitations of their study was the inability to use a placebo control and an "expectancy effect" may play a role in the results, meaning when people expect to feel better from something they generally do. The data was also from a self-selected sample of cannabis users, and there was variability in the results which means that not everyone experienced the same reductions in symptoms after using cannabis. However, Cuttler said this analysis of user-provided information via the Strainprint app was especially valuable because it provides a large data set and the participants were using market cannabis in their home environment, as opposed to federally grown cannabis in a lab which may affect their responses. Strainprint's app is intended to help users determine which types of cannabis work the best for them, but the company provided the WSU researchers free access to users' anonymized data for research purposes. Cuttler said this study points out that further research, particularly clinical trials on the cannabis constituent CBD, may reveal a therapeutic potential for people with OCD. This is the fourth study Cuttler and her colleagues have conducted examining the effects of cannabis on various mental health conditions using the data provided by the app created by the Canadian company Strainprint. Others include studies on how cannabis impacts PTSD symptoms, reduces headache pain and affects emotional well-being. https://www.newkerala.com/news/2020/184525.htm Bongme
  4. hi MediPharm Labs Initiates Clinical Trial for Use of Cannabis to Treat Chronic Kidney Disease Patients and Improve Quality of Life Clinical trial will evaluate the effectiveness of MediPharm Labs proprietary GMP cannabis-derived formulations and medical products and expand MediPharm Labs owned IP In the United States, 37 million or more than 1 in 7 adults, are estimated to have chronic kidney disease (CKD) and Worldwide, approximately 1 in 10 people suffer from kidney disease according to the National Kidney Foundation Patients with CKD suffer from various symptoms and have limited life expectancy, consequently, optimizing quality of life (QOL) is of high priority BARRIE, Ontario, Oct. 19, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc., has initiated a clinical trial to research and evaluate the effectiveness of MediPharm Labs’ proprietary cannabis-derived medical products and formulations on the treatment of end-stage renal disease or Chronic Kidney Disease (“CKD”), a leading and fast-growing cause of death worldwide. MediPharm Labs has chosen to partner with Canadian firm, OTT Healthcare Inc. (“OTT”) and signed a Master Clinical Studies Agreement (the “Agreement”). As the expert principal investigator, OTT will study the pharmacokinetic (dosing) and safety profile of cannabinoid formulations for the Chronic Kidney Disease patient population and assess pain and Quality of Life (“QOL”) scores of patients receiving MediPharm Labs proprietary product formulations. Data gathered will support follow-on randomized double-blind clinical trials to establish the safety and efficacy of these products. Results of these activities including all intellectual property (“IP”) and inventions will be owned by MediPharm Labs. “This Agreement is very meaningful for MediPharm Labs as it signals our dedication, as a specialized pharmaceutical company, to sponsoring and directly participating in the intense and ongoing scientific research necessary to bring the benefits of medical cannabis to those in dire need worldwide,” said Pat McCutcheon, CEO of MediPharm Labs. “The particular area of focus for this very significant Agreement is vitally important. Renal disease is the 11th leading and 6th fastest-growing cause of death globally and those with it suffer from pain, pruritus (severe skin itch), impaired sleep, depression and fatigue. We believe deep research into the use of medical cannabis to treat the effects of this devastating condition is long overdue.” According to the Canadian Journal of Kidney Health and Disease, physical and psychological symptom burden in patients with advanced CKD is significantly debilitating; yet, it is often inadequately treated. Additionally, patients with CKD have limited life expectancy (estimated residual life span is approximately 8 to 4.5 years after dialysis initiation for those aged 40 to 64 years, respectively. Consequently, optimizing quality of life is of high priority. While patients may look to medical cannabis use in symptom management (including common symptoms encountered in advanced stages of CKD such as chronic pain, nausea and vomiting, anorexia, pruritus, and insomnia), its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. MediPharm Labs and OTT Healthcare will co-develop the study drugs that will be evaluated and name each Principal Investigator physician. The Principal Investigators will be accountable to MediPharm Labs for the direction of each study and will be chosen because of their leadership in the field of Nephrology. Before each study begins, all necessary approvals from relevant regulatory authorities including Health Canada will be obtained. By providing tangible evidence of the benefits of medical cannabis, clinical trials of this nature set the stage for the development of safe, effective pharmaceutical-grade products. “MediPharm Labs has established itself as a producer of pharmaceutical quality cannabis API and formulations. With our capabilities and research and development team, we are well positioned to support these trials and provide novel formulations including products from our portfolio and in general to expand our contribution to Nephrology,” said Mr. McCutcheon. “In broader terms, initiating this clinical trial demonstrates our growing maturity as a research-driven pharmaceutically focused company with global aspirations.” MediPharm Labs is contributing to the advancement of medical cannabis in a variety of ways. In July 2020, it joined in a ground-breaking collaboration between University Health Network (“UHN”) and Medical Cannabis by Shoppers Inc. that will use blockchain technology to track medical cannabis products from seed to sale. In late 2019, it received its Cannabis Research Licence under Health Canada’s Cannabis Act and Cannabis Regulations to conduct controlled human administration trials of dried cannabis, cannabis extracts and concentrates, distillates, oil, edibles, topicals and terpenes at its state-of-the-art production facilities. KIDNEY DISEASE FACTS According to the National Kidney Foundation chronic kidney disease, or CKD, causes more deaths than breast cancer or prostate cancer. It is the under-recognized public health crisis. It affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults) and approximately 90% of those with CKD don’t even know they have it. 1 in 3 American adults (approximately 80 million people) is at risk for CKD. CKD is more common in women (15%) than men (12%). CKD is the 9th leading cause of death in the U.S. In 2017, over 500,000 patients received dialysis treatment, and over 200,000 lived with a kidney transplant. Worldwide, approximately 1 in 10 people have kidney disease. One in three people in the general population is at increased risk of CKD. Global estimates indicate that 9 in 10 of those with CKD and are unaware of their condition. An estimated 1 million people die each year from untreated kidney failure. Those with CKD are up to 20 times more likely to die of other causes (mostly cardiovascular disease) before they reach end-stage renal disease. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and completed commercialization of its Australian extraction facility which generated its first revenues in H1 2020. MediPharm Labs Australia was established in 2017. For further information, please contact: Laura Lepore, VP, Investor Relations Telephone: +1 416.913.7425 ext. 1525 Email: investors@medipharmlabs.com Website: www.medipharmlabs.com https://finance.yahoo.com/news/medipharm-labs-initiates-clinical-trial-110100823.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJXKN5pwlJsUO_6v20xM4_sYYM4jUnbDPlTZBphkvAbzJ0eja3C7mfFiCe29IpVXuNGOLsl2X95FX-pBmL55_CaBJLvHv3yHJWSEMmbtWJ1_Rg6h4lkVYefGTCojTXLJURBtlGB9fP5LbSd33t35jfaa7k655pV4YPTVppI-UgXT Bongme
  5. hi Doctor’s advice on using cannabis to treat anxiety and depression When many people hit this wall of distress, they begin self-help. We are in a very stressful time in our lives. For those who have a history of anxiety and depression, the current worldly troubles can lead them back into or worsen these ill feelings. For those who have never had anxiety or depression before, this can be the beginning of a difficult time. It can be overwhelming to think of COVID-19, job insecurity, food and housing insecurity, managing schooling for children, racial issues and typical stressors of life for an extended period of time. But, unfortunately, this is where we are without a specific timeline as to when it will sort itself out. Having an open discussion with family, friends or healthcare providers about personal mental health issues can be frightening. This is an important topic that needs to be addressed. Without facing the issues, depression and anxiety can worsen. We all know someone who is struggling whether that be ourselves or others. We need to be aware of symptoms such as pessimism, feelings of hopelessness, decreased energy, sleep disorders, decreased interest in hobbies and activities such as sex, persistent physical symptoms that do not respond to therapy, suicidal thoughts or attempts. Unfortunately suicide has been the second most common cause of death in people aged 15 to 29. When many people hit this wall of distress, they begin self-help. When this therapy involves exercise, meditation or talking to friends, it can be very therapeutic. When this involves overuse of alcohol or drugs, it can become dangerous. So my question is: where does cannabis fit into this picture of therapy for anxiety and depression? We have many people using medical marijuana for anxiety/depression. There are also many who are self-medicating with recreational marijuana. Unfortunately, the studies regarding cannabis and depression/anxiety have mixed results. The studies themselves are done with difficulty since cannabis is a Schedule 1 drug in the U.S. Often the dosage of the drug is incompletely known since the drug is supplied by the patient. Insomnia can promote depression or be caused by it. Many people use THC/CBD to help them sleep. In many cases, this works well. For others, it causes increased anxiety and sleeplessness. It has been reported that the sleep architecture of cannabis induced sleep has a smaller REM component. This component of sleep is important for memory and mood. Does cannabis improve or worsen depression? Some studies have shown that increasing cannabis use is related to increasing depression. But the question I would ask is this: Does the cannabis cause worsening depression or do people who become more depressed tend to use more cannabis to attempt to alleviate the symptoms? Other studies have shown improvement in depression with cannabis use. The study from Yale showed that THC was more effective than CBD in improving some depressive symptoms, making 64 per cent of people more relaxed and peaceful, but worsened motivation in 20 per cent. If a person is having difficulties with depression, I would recommend being evaluated by a physician who specializes in depression before initiating medical marijuana or increasing the dosage. It can be a slippery slope to move from a therapeutic dose to a dosage of abuse. Once the decision to use medical marijuana is made, it is beneficial to enlist the help of a budtender for decisions regarding strains. With regard to depression with oneself or others, this is another case of, “If you see something, say something.” The FreshToast.com, a U.S. lifestyle site that contributes lifestyle content and, with their partnership with 600,000 physicians via Skipta, medical marijuana information to The GrowthOp. Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network https://www.thegrowthop.com/wellness/doctors-advice-on-using-cannabis-to-treat-anxiety-and-depression Bongme
  6. hi How does cannabis impact mental health? “Cannabis and mental health are intimately intertwined,” says Dr. Mark Ware, Canopy Growth’s chief medical officer. Working in family medicine for more than 20 years, Dr. Mark Ware has long witnessed the therapeutic benefits of cannabis, not only to address physical pain and discomfort, but also to treat mental health. Many of Dr. Ware’s patients have chronic pain and have exhausted conventional therapies. Cannabis, in some cases, has helped not only to manage their pain, but also to alleviate the accompanying stress and anxiety. “It was obvious to me very early on that cannabis had a very broad effect on people’s health, including their mental health,” Dr. Ware, chief medical officer for Canopy Growth, told The GrowthOp. “Cannabis and mental health are intimately intertwined.” It’s a relationship, however, that is just starting to be understood. Cannabis is not a singular compound; there are more than 100 cannabinoids in the plant that can produce different, sometimes opposing, effects. Add to that that every person has an individual endocannabinoid system that responds differently to those compounds. Health Canada warns that individuals with a personal or family history of mental illness might be vulnerable to negative mental health outcomes associated with cannabis use. Beyond medical and psychological background, the dose and method of consumption are other factors to consider, Dr. Ware says. “It’s a complex topic. And it’s very difficult to distill it down to simple messages,” he says. “Cannabis and cannabinoids may have therapeutic properties, but they may also have risks. And it’s really important that people acknowledge, talk about and inform themselves about what they’re doing.” The two cannabinoids that get the most attention, cannabidiol (CBD) and tetrahydrocannabinol (THC), can also lead to very different mental health outcomes. CBD has demonstrated potential in treating anxiety-related disorders, psychosis and schizophrenia, while THC can have adverse psychological effects, especially in high doses. On the other hand, THC can also provide therapeutic benefits. There’s also much more at play than just THC and CBD. Cannabis plants also contain hundreds of terpenes, some of which are believed to have positive impacts on mental health. Limonene, which is found in citrus fruits, may help combat depression, anxiety and stress. Linalool, found in lavender, could help reduce anxiety. How the terpenes and cannabinoids intertwine and work together, especially in the context of anxiety and mood disorders, is an ongoing topic of research. “There’s still a vast amount of knowledge about cannabis and cannabinoids that we have yet to discover,” Dr. Ware says. As Canada approaches two years of legalization, and other countries start to rethink their approach to cannabis, research is proliferating, especially in regards to CBD, which has shown promise for treating a range of psychiatric disorders. Legalization has helped change the conversation about cannabis and mental health, Dr. Ware says. “People have gone from thinking of cannabis as a drug, which is very detrimental to mental health, causing psychosis and mental illness and being associated with substance abuse and addiction, to the world where we’re actually thinking of cannabis as having positive effects and potentially therapeutic benefits,” he says. “It’s really been a remarkable transformation.” https://www.thegrowthop.com/cannabis-news/how-does-cannabis-impact-mental-health Bongme
  7. hi Smoking weed may worsen pain after surgery Aside from increasing acute pain, those who used marijuana prior to surgery also showed that they required more anesthesia during the surgical procedure. he notion that marijuana could help prepare individuals for a surgical procedure has been thwarted by new research. Smoking weed will not ease the pain but does the opposite, as it could make the pain worse during recovery. Research presented at the American Society of Anesthesiologists' annual meeting on Monday revealed that while there may be evidence that cannabis could prove beneficial for chronic and nerve pain, they have uncovered evidence that such is not the case for an acute kind of pain. An example of acute pain that researchers referred to is pain from a surgery of a broken bone. Aside from increasing acute pain, those who used marijuana prior to surgery also showed that they required more anesthesia during the surgical procedure. It must be noted that there are instances when undergoing anesthesia becomes risky for a number of individuals like the elderly or those who are suffering from chronic illnesses like diabetes. The researchers analysed the records of 118 patients who underwent surgery at the University of Colorado Hospital for the repair of a fractured tibia, or the shinbone, or calfbone. They found that 30 patients admitted to using cannabis before the surgery albeit there was no indication of the timing, the type of cannabis that was used, as well as the frequency. The researchers then compared two groups, those who used cannabis prior to surgery and those who did not. They evaluated the amount of anesthesia given during surgery, the pain scores of the patients, and the amount of opioids that were used at the hospital after the procedure. Patients who used cannabis required more anesthesia, experienced more pain during recovery, and also received more opioids daily while they were at the hospital. The researchers noted that an anesthesiologist would increase the levels of anesthesia upon seeing signs that the patient is in pain. These signs would include involuntary body movements, high blood pressure, increased heart rate, and rate of breathing. Dr Ian Holmen, an anesthesiologist at the University of Colorado Hospital, revealed that the study underscores the importance for patients to inform their anesthesiologists if they used marijuana or any cannabis product before surgery, including the use of non-opioid alternatives. This will ensure that they would receive the best anesthesia that will ideally control the pain. He also noted that more research is needed to better understand how cannabis would impact pain. https://www.ibtimes.co.uk/smoking-weed-may-worsen-pain-after-surgery-1684205 Bongme
  8. hi Medicinal cannabis may play a significant role during COVID-19 Early studies indicate that medicinal cannabis may have potential in treating the symptoms of COVID-19. COVID-19 shows no sign of slowing down just yet and vaccines are still several months away, perhaps even a year. The rush to try drugs already on the market has led to dramatic purchases by some governments in a bid to reduce the impact of such an insidious virus. With so many health professionals looking for a cure – or, failing that, the best preventative strategy aside from masks and social distancing – it is worthwhile taking a step back to see what role medicinal cannabis may play in helping to reduce the severity of symptoms brought about by COVID-19. How does the coronavirus work? COVID-19 uses its spiky surface proteins to grab on to receptors found on healthy cells, particularly those found in the lungs. These viral proteins distinctively go through ACE2 receptors; and once they have made their way inside, the coronavirus seizes healthy cells and takes command. Eventually, it kills some of the healthy cells. The virus impacts the respiratory system by moving down your respiratory tract, which includes your mouth, nose, throat, and lungs. However, because the lower airways have more ACE2 receptors than the rest of the respiratory tract, COVID-19 is more likely to go deeper than other viruses such as the common cold. This is what makes COVID-19 more sinister than average colds or strains of influenza. By entering the lungs, the virus makes it difficult for people to breathe, particularly if it leads to pneumonia. For most people (about 80%), the symptoms end with a cough and a fever. For those who are not so lucky, the infection can become very severe. About five to eight days after symptoms begin, some people will have shortness of breath which could lead to acute respiratory distress syndrome (ARDS) a few days later. What can cannabis do? Cannabinoids such as cannabidiol (CBD) have a history of safe use and contain several properties which may be useful in treating certain medical symptoms: CBD has anti-inflammatory properties, can act as a vasorelaxant and has the ability to reduce pain and anxiety. In combination with other cannabinoids and terpenes, as well as necessary clinical intervention, CBD has much potential to treat the symptoms of a virus such as COVID-19. Whole plant cannabis extracts have also been shown to reduce blood coagulation in animal models; it is known that many of the negative systemic effects of COVID-19 appear to be related to altered coagulation, so it is possible that cannabis may be useful in managing these sequelae. Can medicinal cannabis help to prevent or treat COVID-19? Prevention To date, the range and scope of verifiable research data linking cannabinoids with COVID-19 prevention is highly limited; however, novel approaches to the prevention of COVID-19 include a single study examining the possibility of incorporating CBD into oral solutions, such as mouthwashes and throat gargling liquids, with a view to ‘lowering or modulating ACE2 levels in high-risk tissues’. Studies have found that ACE2 levels change during the progression of COVID-19 and therefore the ability to modulate these levels becomes particularly important as ACE2 has been shown to be essential for lung function in animal models of SARS viruses. Reducing severity and impact In analyses of COVID-19 there has been a significant degree of interest in the phenomenon of cytokine storm syndrome, wherein too many cytokine proteins are released in the body: these proteins can attack the lungs and overwhelm the immune system with hyperinflammation. Early evidence has tentatively indicated that CBD and THC may be beneficial in the treatment of patients whose bodies’ inflammatory response has become pathogenic. Much research in this field has focused on the ability of cannabinoids and terpenes to lower the immune system’s response without suppressing it. Early findings in a study currently being conducted by terpene manufacturer Eybna and cannabis research and development firm CannaSoul Analytics, both from Israel, appear to indicate that the combination of terpenes and cannabinoids used is up to two times more effective than the corticosteroid dexamethasone, when used to reduce inflammation from COVID-19. The study has not yet been peer reviewed. Another new approach currently being investigated in Israel is the development of a potential cell therapy treatment which uses CBD-loaded exosomes to treat COVID-19 patients. The intention of this technology is to ‘target both central nervous system indications and the COVID-19 coronavirus’. CBD-loaded exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties by targeting specific damaged organs, such as infected lung cells. What can be done to increase research in this field? Research into the medicinal potential of cannabis is notorious for the complexity of its application processes and the difficulty of sourcing cannabis. In Australia, using CBD only – with no THC content – in research activities requires the academic institution to apply for a special licence to allow it to obtain and store the cannabinoid, because it is still a Schedule 9 drug despite having no psychoactive properties. The COVID-19 pandemic is likely to continue for many months yet; and this may not be the last novel coronavirus we face in our lifetime. Therefore, it is incumbent on all governments to make studying the potential of alternative medicine, such as cannabis, much easier for research institutions and private laboratories to undertake. References 1 Coronavirus: what happens when you get infected? WebMD: https://www.webmd.com/lung/coronavirus-covid-19-affects-body#1. 2 C. Coetzee, R.-A. Levendal, M. van de Venter, C.L. Frost. Anticoagulant effects of a cannabis extract in an obese rat model. Phytomedicine 14 (2007) 333–337. 3 Kander, T. Coagulation disorder in COVID-19. https://doi.org/10.1016/ S2352-3026(20)30217-9. 4 Wang, B.; Kovalchuk, A.; Li, D.; Ilnytskyy, Y.; Kovalchuk, I.; Kovalchuk, O. In search of preventative strategies: novel anti-inflammatory high-CBD Cannabis Sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Preprints 2020, 2020040315 (doi: 10.20944/preprints202004.0315.v1). 5 Mabou Tagne A, Pacchetti B, Sodergren M, et al. Cannabidiol for viral diseases: hype or hope? Cannabis Cannabinoid Res. 2020;5:121–131. 6 InnoCan Pharma collaborates with Tel Aviv University to develop a new revolutionary approach to treat the COVID-19 coronavirus with exosomes-loaded CBD. https://finance.yahoo.com/news/innocan-pharma-collaborates-tel-aviv-204600158.html. https://www.healtheuropa.eu/medicinal-cannabis-may-play-a-significant-role-during-covid-19/103093/ Bongme
  9. Hi Cannabis seeds: the little power-seeds Many trendy foods are quickly named “superfood”. However, cannabis seeds have truly earned this title. We will explain to you the positive effects these small powerhouses have on your body and your health. On the other hand, if you wish to collect some of the most acclaimed cannabis seeds such as OG Kush, White widow seeds or other famous BSF Seeds, you can now find the best weed seeds online on SensorySeeds.com. The small, brown-green cannabis seeds They are small nutlets and closely with the hops used. The cannabis seeds have a nutty, sweet taste and are reminiscent of sesame. Unpeeled seeds have a slightly bitter aftertaste due to the bitter substances in the skin, but they have more valuable ingredients than peeled ones. The fact that the cannabis plant can be used in many ways was recognized 10,000 years ago in ancient Asia. Especially in Egypt and China, the seeds were an essential part of the diet and herbal medicine. In India, Germany, Greece and Iraq, the cultivation of industrial hemp can be proven in earlier times. Cannabis seeds don’t get you high To anticipate any concerns, those who eat cannabis seeds will not get high. For the food industry, crops are bred that do not contain the intoxicating agent tetrahydrocannabinol (THC). For the seeds to be consumed safely, it is legally stipulated that they must not exceed a THC content of 0.2%. Tested cannabis and hemp seeds are therefore THC-free. Cannabidiol is another legal active-ingredient in industrial hemp, can have a slightly sedating effect in large quantities on people who are particularly sensitive to cannabinoids. Cannabis is healthy Along with quinoa and soy, hemp is one of the few plant sources that can meet the human protein needs. For vegetarians, vegans and people with conscious meat consumption, cannabis seeds are a plant-based alternative to supply their body with sufficient proteins. They contain all the essential amino acids that humans need for life because the body cannot produce essential amino acids on its own but has to absorb the proteins through its diet. The organism then converts the amino acids into endogenous proteins. These are essential for body growth, metabolic processes, muscle building, the production of messenger substances, enzymes and hormones – in short: They ensure that everything in our body runs smoothly. Hemp protein is very similar to the human one Besides, the human body can digest and process the plant-based hemp seed protein very well. Because 60% of the vegetable protein consists of edestin, which is very similar to human blood plasma. It makes it easier for our organism to convert the protein into immunoglobulin, which maintains our defense mechanisms. The component albumin, which stimulates the production of antibodies, also boosts the immune system. The amino acids also have a vasodilating effect and have a detoxifying effect. Cannabis seeds are ideal suppliers of omega-6 and omega-3 fatty acids Another advantage of hemp is healthy fatty acids. There are two fatty acids in large quantities that play an essential role in the body’s immune response. Cannabis seeds provide omega-6 and omega-3 in a healthy 3: 1 ratio. For comparison, in our diet, the two fatty acids should ideally be represented at < 5: 1. Omega-6 and Omega-3 stimulate cell regeneration and ensure that we are physically and mentally efficient, and muscles are built up quickly. That is why cannabis seeds are an ideal nutritional component for athletes. Gamma-linolenic acid: a rare and healthy fatty acid In cannabis seeds, there is a speciality among the fatty acids: gamma-linolenic acid (GLA). This unsaturated omega-6 fatty acid is only found in significant quantities in evening primrose oil, pomegranate seed oil, spirulina, black currant and borage seed oil. In interaction with vitamins B3, B6 and C, GLA creates a tissue hormone that has many positive effects: It has an anti-inflammatory effect, lowers blood pressure, dilates blood vessels and reduces cholesterol. Cannabis against symptoms of PMS and menopause Research suggests that GLA can relieve discomfort during menstruation and menopause. The reason for this could be the hormone-regulating effect of GLA on the thyroid and pancreas. It is assumed that during certain cycle phases, there is an imbalance in hormones and nutrients, which can lead to various complaints. The rich cannabis seeds can compensate for this deficiency. Besides, the GLA inhibits the release of inflammation-promoting substances and reduces the symptoms. Always drink a lot with cannabis seeds Hemp seeds provide plenty of fibre. While insoluble fibre has a positive effect on intestinal activity, soluble fibre delays the absorption of glucose. It prevents strong fluctuations in the blood sugar level and reduces the production of insulin. This effect helps to maintain a healthy weight and prevent type 2 diabetes. With so many health benefits, one should not overdo the consumption of the small cannabis seeds. Like chia seeds, cannabis seeds tend to swell in the stomach and store a lot of fluid. If the stomach is not used to a high-fibre diet, digestive problems can occur. To avoid unpleasant effects, you should start small. To slowly get the intestines used to cannabis seeds, we recommend a teaspoon per day. Adults who use hemp seeds as a complete source of protein are considered the ideal daily amount of 50-75 grams; for children, it is 25-40 grams daily. The higher the daily ration, the more fluid the body needs for a balanced water balance. https://www.abcmoney.co.uk/2020/09/25/cannabis-seeds-the-little-power-seeds/ Bongme
  10. hi Key cannabis chemical may help prevent colon cancer, researchers say COLUMBIA, S.C. — A chemical in marijuana may be able to help prevent colon cancer, according to a new study from top University of South Carolina researchers. The study, published in iScience, found that mice injected with THC and a cancer-causing chemical did not develop cancer. Mice in a control group were injected with the carcinogen but no THC, causing them to develop cancer. “We were really excited to see those results, which were so dramatic,” said co-author Prakash Nagarkatti, who is the University of South Carolina’s vice president of research. THC — the chemical in cannabis that causes a “high” — prevented cancer from emerging in mice by reducing inflammation in the colon, said Nagarkatti, who is one of America’s leading marijuana researchers. This could be useful for people who have illnesses such as Crohn’s disease and colitis, where long-term inflammation increases risk of cancer, Nagarkatti said. “We clearly need to do clinical trials and additional research needs to be done,” Nagarkatti said. Chronic inflammation is also thought to increase risk for other types of cancer, such as breast cancer, pancreatic cancer and prostate cancer, Nagarkatti said. “There are quite a few of these cancers that are triggered by chronic inflammation,” Nagarkatti said. Nagarkatti’s conclusion corroborates anecdotal evidence THC may be effective in helping humans with illnesses like Crohn’s that cause chronic inflammation, he said. In states where medical marijuana is legal, many people with inflammatory bowel disease who have tried using marijuana have reported to their doctors it lessened symptoms and improved quality of life, Nagarkatti said. While colonoscopies have reduced the amount of colon cancer in older Americans, more Americans in their 40s are getting colon cancer, Nagarkatti said. Perhaps the most public example of this recently was Chadwick Bozeman, the South Carolina native and star of “Black Panther,” who died late last month at age 43 from colon cancer. Mitzi Nagarkatti, the chair of the university’s department of Pathology, Microbiology and Immunology who is married to Prakash, is listed as a co-author on the study. The duo have recently published multiple studies on chemicals found in marijuana. Recently, they published a study that found THC may be able to treat a deadly complication of COVID-19 by tamping down a harmful immune system response to the coronavirus. ——— ©2020 The State (Columbia, S.C.) https://www.rawstory.com/2020/09/key-cannabis-chemical-may-help-prevent-colon-cancer-researchers/ Bongme
  11. hi Can cannabis be a substitute for prescription drugs? In order for a prescription drug to reach the market, it must be extensively studied, first in animal and then in human clinical trials. Safety, efficacy, and risks must be determined. But as anyone who has seen a commercial for a prescription drug knows, there are still side effects. There are risks in stopping a prescription. And, of course, there are the risks of addiction. Prescription opioid painkillers have increased drastically from common-use pill to massive public health crisis. At the same time, the perception of marijuana has shifted away from it as a gateway drug to using it as medicine. Now, several recent studies show that public opinion is shifting to the point of substituting cannabis for opioids and other prescription drugs that have high risks or low efficacy. In addition to opioids, drug substitution is most common for benzodiazepines, like Valium or Klonopin, and antidepressants. The benefits of substituting a substance for an addictive drug seem obvious, but there is a serious hidden risk in doing so without talking to a doctor. For example, with CBD, its interactions with prescription drugs have barely been studied. Complications can arise from drug interactions and withdrawal symptoms, resulting in incorrect dosages and potentially unknown side effects. Patients are substituting prescriptions with cannabis With unregulated whole-plant and hemp-derived CBD easily available online and in grocery stores across the United States, as well as recreational and medical cannabis in shops in the US and Canada, some people are doing just that. One specific substitution holds promise, but also danger: benzodiazepines. Benzos—such as Klonopin (clonazepam) and Valium (diazepam)—are commonly prescribed for anxiety, insomnia, seizures, alcohol withdrawal, and muscle spasms, all of which also have the potential to be treated with medical cannabis, especially CBD. But unlike CBD, benzodiazepines have been around the scientific block, completing the clinical trial process and landing on the market in the 1960s. Also unlike CBD, they are known to be addictive. “There’s this great opportunity because of the opioid crisis to find alternatives,” said Dr. James Corroon, Medical Director at the Center for Medical Cannabis in California, who published a study on cannabis substitution for pharmaceutical prescriptions last year. Of 2,774 participants, 46% reported substituting cannabis for a pharmaceutical drug. “There’s reason to be hopeful,” he said, “but we need more data.” There’s also reason to be concerned. Self-identified “medical” consumers were about five times as likely to substitute drugs with cannabis than recreational consumers, according to the study. And almost a quarter of recreational consumers also reported substitution. Non-prescribed swapping of THC or CBD for a prescription drug often occurs accidentally at first: A chronic pain patient might smoke marijuana recreationally and notices it helps; an insomnia patient might eat a CBD chocolate for anxiety but then is able to sleep; a person might get a medical marijuana card for anxiety and discover it helps with pain and insomnia. While this might seem like a serendipitous coincidence for patients, the pattern is a warning to doctors. “These people aren’t getting the right care,” said Dr. Corroon. The concern is with drug interactions. If you add CBD to a drug regimen of an opioid or a benzo, it creates an amplification effect, Dr. Corroon explained. With CBD and Valium, for example, the liver metabolizes CBD first. The Valium is then sent back into the bloodstream, allowing the same dose to last longer. As a result, the patient may be unintentionally overmedicating. This also means a patient could be prescribed a lower dose of Valium to experience the same relief. This can be great if a healthcare worker is supervising a patient and their drug substitutions, but doses of benzos need to be slowly decreased to be safely stopped, regardless of whether another drug is added. Rapid decreases of any drug can be dangerous. Benzodiazepines depress the central nervous system and an abrupt change can leave the brain struggling for balance. Benzodiazepine withdrawal can cause a return of symptoms, additional anxiety, insomnia, and flu-like symptoms. More severe symptoms include panic attacks, hand tremors, depression, and seizures. Without medical advice and supervision, a person could experience withdrawal, unnecessarily low or high doses, or vacillation between the two as anxiety decreases and returns, said Dr. Corroon. Can cannabis help? Cannabis treatment is being broadly studied as a partial or full substitution for opioids, but research is just beginning on its possible use in reducing benzodiazepine use. “There is a role for benzodiazepines in clinical practice,” said Dr. Chad Purcell, a surgical resident at Dalhousie University. But there’s an issue with benzodiazepines that is similar to that of opioids, he said. In a small study, Dr. Purcell and his associates analyzed information provided by patients new to cannabis treatment who were already taking benzodiazepines. Almost a third stopped their benzodiazepine treatment within two months. And almost 45% ended use by four months. “There seems to be something at play here,” Dr. Purcell said. But he cautioned against drawing a direct line between the two. Just because two things happened—starting cannabis and stopping benzodiazepines—doesn’t mean one caused the other. Another recent study, led by Dr. Phillipe Lucas, VP of Patient Research at cannabis producer Tilray, showed high trends of cannabis substitution across all types of prescription drugs. Dr. Lucas and authors analyzed cannabis use patterns and substitutions of 2032 Canadian medical cannabis patients who responded to a survey. Many participants reported more than one substitution. About 45% reported substituting cannabis for alcohol, 31% substituted it for tobacco, and 26% substituted it for illicit drugs. A whopping 69% reported substituting cannabis for prescription drugs. Unsurprisingly, opioids were the most common among pharmaceutical substitutions, at 35%. Antidepressants and anti-anxiety prescriptions came in close behind at 21%. Detailed questions revealed that chronic pain and mental health issues were the two most common reasons participants took cannabis, both at just under 30%. Chronic pain is often accompanied by mental health conditions, especially anxiety and insomnia, said Dr. Lucas. It’s a common trifecta of diseases and a troubling one. The conditions can exacerbate each other and the knot of symptoms can be difficult to untangle. It’s not uncommon for endless pain to cause severe anxiety and prevent sleep, Dr. Lucas said. Roughly half of participants reported experiencing all three as primary symptoms, according to the study. Patients experiencing this medical triad often take more than one daily prescription as treatment, so it’s not surprising that many study participants substituted for more than one drug, Dr. Lucas explained. And it’s possible that, if a cannabis substitution could more effectively treat a root cause of chronic pain, medications for anxiety, insomnia or depression could become unnecessary. For those people who are making a conscious choice to substitute, and doing so with medical guidance, there seems to be only an upside. It’s the people who accidentally substitute or self-prescribe that worry Dr. Lucas. “It gives me great concern.” Stay informed and healthy Always talk to your doctor before starting or stopping a new medication. Ask about potential prescription interactions and options. If you already take a prescription medication, talk to your prescribing physician about your marijuana and/or CBD use. https://www.leafly.com/news/health/can-cannabis-be-prescription-drug-substitute Bongme
  12. hi New Guidelines Issued on Medical Cannabis for Chronic Pain Chronic pain patients can be treated with medical cannabis following one of three protocols based on patient characteristics, according to an international task force at the virtual PAINWeek meeting. Citing limited clinician knowledge about medical cannabis treatment and the opioid crisis, one task force member said the recommendations are timely. "We as a task force believe it's extremely important to bring [medical cannabis] to patients," Alan Bell, MD, of the University of Toronto, told MedPage Today. "Our main focus was to provide directions to clinicians." Medical cannabis has been suggested to treat chronic pain, the task force noted, but too many providers still do not utilize it because there has not been accepted guidelines about dosing and administration. Others prescribe medical cannabis without knowing how patients can properly dose. "There's a huge knowledge gap and no way clinicians can fall back on a specified dosing regimen," Bell said. Led by Arun Bhaskar, MD, of Imperial College Healthcare NHS Trust Pain Management Centre in London, the 20-clinician Global Task Force on Dosing and Administration of Medical Cannabis in Chronic Pain used a modified Delphi process. Among their recommendations: Treat the majority of patients along the "routine" scale. This means starting patients with 5 mg of cannabidiol (CBD) twice daily. Tetrahydrocannabinol (THC) should only be introduced if patients do not respond to at least 40 mg of CBD daily, starting with 2.5-mg daily THC doses. THC doses should be capped at 40 mg daily. Frail and elderly patients, and those with severe co-morbidity or polypharmacy should be treated via a conservative route. This means starting the THC dosses at 1 mg daily and titrating up the THC more slowly. Patients suffering from severe pain and those who have significant prior cannabis consumption can follow the rapid protocol. This mean starting with a CBD-THC balanced dose of between 2.5-5 mg per each compound once or twice daily. "Tailoring medical cannabis treatment to the individual is a critical component of successful treatment," according to the group's poster presentation at PAINWeek. The task force recommends starting with CBD in most cases because they have seen many patients benefit solely from CBD. Unlike THC, CBD does not have psychoactive properties. The task force encourages providers to consider medical cannabis for patients dealing with neuropathic, inflammatory, nociplastic, and mixed pain. The task force did not set a maximum treatment age; many of its clinicians reported seeing best results among geriatric patients, Bell said. They did not set a minimum CBD treatment age, with many treating pediatric patients with high doses of CBD for epilepsy. The task force did not set a minimum treatment age for THC because they could not come to an agreement, Bell said. That does not mean they endorse treating minors with THC; the brain's neuroplasticity until age 25 eliminates that possibility, Bell said. They suggested the best administration method is oral because of "ease of dosing and safety," according to the poster. They recommended pregnant and breastfeeding women, and people with psychotic disorders, not be administered medical cannabis. They also cautioned against mixing medical cannabis with anticoagulants, immunotherapy, or the epilepsy medication clobazam (Onfi, Sympazan, Frisium). The task force needed 75% agreement to adopt any resolutions and Bell said they agreed to most of their recommendations on the first vote. "There's way too much of opioids being used for chronic pain despite a lack of evidence and the harms associated with opioids," Bell said. "We feel this is a major barrier that we are trying to overcome...that may exist because of the knowledge gap" regarding medical cannabis. The task force featured clinicians from North America, Brazil, Europe, Australia, and Africa, according to the poster. It also included clinicians "with many, many years" of clinical experience working with medical cannabis, Bell said, from practices ranging from primary care to oncology to pediatrics and more. They began the consensus process by completing clinical practice surveys, then reviewed questions and attended two virtual meetings. https://www.medpagetoday.com/meetingcoverage/painweek/88593 Bongme
  13. hi Cannabis and COVID-19? Can CBD and nitric oxide prevent the spread of COVID-19? That’s the question three Thompson Rivers University researchers want to answer. Doctors Joanna Urban, John Church, and Kingsley Donkor are working toward the development of an antiviral nasal spray and mouthwash using CBD extracts, terpenes (a type of organic compound) and nitric oxide. "We're finding the perfect formulation," says Dr. John Church. The research group says it might be a while before a vaccine is released, so this preventative measure could make a huge difference in the spread of the virus. "Let's block the virus from entering our bodies," Church continues. "We want to block cell entry and but also wipe the virus out so it can't gain a foothold in our bodies." "Additionally, cannabanoids and nitric oxide have the anti-inflammatory effect, so they prevent inflammation," Dr. Urban notes. For people who dislike synthetic chemicals, the trio hopes to make the end product as natural as possible. "It's going to be safe, because most of the reagents that are going to be involved in this project have all been regarded as safe through Health Canada. Be it a nasal spray or the mouthwash, it should be safe for humans to apply," adds Dr. Donkor. Dr. Church says the nasal spray and mouthwash would be most effective for those who are unable to physical distance. "People could take the nasal spray or gargle before the start of the shift and then when they're done after they could take that before they go home for their families," Church explains. "I really see this as being effective for our front line workers." "So many of the mortalities, a big percentage, has actually been the front line workers that put their life on the line. So I imagine, wouldn't it be great if you've got people in the ICU and either the nurses or the doctors could take a couple shots up their nose and a gargle and we believe it would give you very effective coverage at the start of the shift and at the end of the shift before they go home." The doctors say if they can come up with the right formula soon, they could have this product in people's pockets between 6 months to a year. https://www.castanet.net/news/Kamloops/310239/Three-doctors-are-working-on-developing-a-cannabis-and-nitric-oxide-product-to-prevent-COVID-19 Vid Onlink Bongme
  14. hi Here’s how cannabis can help fight chronic gut problems Though cannabis provides therapeutic value for those with IBD, its primary benefit doesn’t really seem to have to do with pain. A primary reason that many patients turn to medicinal cannabis is to treat chronic pain. In fact, a 2019 study published in the journal Health Affairs found that more than 62 per cent of medical marijuana patients were using the plant to relieve pain symptoms. Those with chronic gut issues also experience intense pain, and reports are that patients with Inflammatory Bowel Disease (IBD), such as Crohn’s and ulcerative colitis, have begun using medicinal cannabis to treat their symptoms. Though cannabis provides therapeutic value for these people, its primary benefit doesn’t really seem to have to do with pain. Until fairly recently, it wasn’t clear exactly why cannabis was so effective in treating chronic gut problems. But a 2018 study published in the Journal of Clinical Investigation was able to show the physical manner in which cannabis attacks IBD. Researchers weren’t initially looking for weed’s effect on the microbiome, but rather stumbled upon the answer. What they found was that the cannabis was treating inflammation. Previous studies have shown how cannabis is a useful anti-inflammatory, but it works somewhat differently with IBD. A thin layer of cells, called epithelial cells, separates the gut from the rest of the body and the cells are responsible for regulating different mechanisms, like controlling how many neutrophils enter. Neutrophils are a kind of white blood cell that traverses the gut and consumes microbes. When too many neutrophils slip inside and kill peaceful microbes and the gut itself, it causes IBD in patients. But researchers discovered that epithelial cells aren’t the only the gateway that controls what gets in the gut. As Beth McCormick, a professor in the Department of Microbiology and Physiological Systems at the University of Massachusetts, and others discovered, the endocannabinoid system also contributes. Think of the endocannabinoid system acting as a regulatory system for the gut. Not everyone produces enough cannabinoids to assist in it functioning properly, which helps explain why ingesting cannabinoids through cannabis has proven effective for patients. “There’s been a lot of anecdotal evidence about the benefits of medical marijuana, but there hasn’t been a lot of science to back it up,” said McCormick, co-author of the study. “For the first time, we have an understanding of the molecules involved in the process and how endocannabinoids and cannabinoids control inflammation. This gives clinical researchers a new drug target to explore to treat patients that suffer from inflammatory bowel diseases, and, perhaps, other diseases as well.” It’s worth mentioning that researchers have not conducted studies on using cannabis-derived cannabinoids to replace those missing in humans with IBD. But the team behind the study reports this could open the door to helping the 1.6 million Americans with IBD. “While this is a plausible explanation for why marijuana users have reported cannabis relieves symptoms of IBD, we have only worked in mice and have not proven this experimentally in humans,” said Randy Mrsny, a study co-author and professor at the University of Bath’s Department of Pharmacy and Pharmacology. “However, our results may provide a mechanistic explanation for anecdotal data that cannabinoid exposure benefits some colitis patients,” Mrsny added. “For the first time, we have identified a counterbalance to the inflammation response in the intestine and we hope that these findings will help us develop new ways to treat bowel diseases.” The FreshToast.com, a U.S. lifestyle site that contributes lifestyle content and, with their partnership with 600,000 physicians via Skipta, medical marijuana information to The GrowthOp. Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network https://leaderpost.com/wellness/heres-how-cannabis-can-help-fight-chronic-gut-problems/wcm/274cdb53-952f-414f-a7dd-dcbd398c8a44/ Bongme
  15. Hi Can you use cannabis to calm dementia? The question: My father has dementia and we have been looking after him at home. The last thing we want to do is put him into a nursing home during the COVID-19 pandemic. But he is a challenge and is agitated at times. I’ve heard that cannabis has a calming effect on people with dementia. Is that worth trying? The answer: Agitation, which includes restlessness, general emotional distress and sometimes aggression, is a major problem for people with dementia, as well as their caregivers. The existing drug treatments – mainly antipsychotic medications – are only modestly successful in lessening agitation, and they also carry risks of harmful side effects. Dementia experts generally agree that behavioural interventions should be tried before turning to these medications. For instance, it may be possible to identify the cause of the agitation and develop a solution or an appropriate distraction, such as music or pet therapy. But, as the disease progresses, agitation tends to get worse and behavioural approaches become less and less effective. So, there is a real need for new treatment options, says Krista Lanctôt, a senior researcher at Sunnybrook Health Sciences Centre in Toronto. This need, she adds, has raised interest in cannabis because it has a wide range of effects on the brain, some of which might help deal with certain troubling dementia symptoms. But only a handful of small studies have actually explored the use of cannabis products in patients with various types of dementia including Alzheimer’s disease. And, so far, the research results have been mixed. One of the most promising studies involved 39 patients with moderate to severe Alzheimer’s. The trial was designed to assess nabilone, a drug that is currently approved for treating chemotherapy-induced nausea. Nabilone contains a synthetic form of tetrahydrocannabinol (THC) – the psychoactive ingredient in cannabis. Each patient received both the real drug and a placebo, in random order, for six weeks. “Nabilone treatment was associated with a clinically and statistically significant reduction in agitation over six weeks, compared to the six weeks on placebo,” says Lanctôt, who led the study. “Also, caregiver distress was significantly lower.” Although the results are promising, Lanctôt says the findings need to be confirmed with more research. She notes that marijuana contains a lot of different cannabinoids. In order to understand their potential effects – both good and bad – it’s critically important to isolate the components and study them in a systematic fashion and in combination if warranted. Lanctôt is already planning a larger study involving 168 patients, who will be divided into three treatment groups. They will receive either nabilone or a placebo, or cannabidiol oil (CBD), a compound derived from marijuana plants. Dallas Seitz, an associate professor of psychiatry at the University of Calgary, agrees that it’s far too soon to recommend cannabis for agitation. “I think it’s good that we don’t jump on the bandwagon right away because there is so much misinformation out there about the potential benefits of cannabis.” Indeed, there is reason for caution, particularly in this vulnerable patient population. Previous research suggests that cannabis may worsen memory. So, cannabis might not be appropriate for people in the early stages of dementia while they still have their cognitive abilities largely intact. Cannabis also has a sedating effect, and that’s not necessarily a good thing. Too much sedation, which is often linked to a higher dosage, can lessen quality of life if a person is sleeping much of the time. It can also increase the chances of having a catastrophic fall. What’s more, cannabis may interact with some medications including warfarin, a commonly prescribed blood thinner. “It could increase the risk of bleeding,” Lanctôt warns. She also points out that the positive findings from her nabilone study offer “absolutely no evidence” that agitation can be eased by recreational and medical marijuana. The synthetic THC in nabilone is structurally different from natural THC, she explains. In fact, a few earlier studies suggest that natural THC does not reduce agitation. To further complicate matters, there is a huge variation in cannabis products, which contain very different ratios of THC to CBD. What’s needed, Seitz says, is a well-studied standardized product. “That would allow us to say that a certain compound, at a specific dose, will have a predictable effect,” he says. In the meantime, some families may still be tempted to try cannabis with their loved ones. If they do so, Lanctôt says, they should seek the guidance of a doctor and a pharmacist to minimize the potential for harm. Paul Taylor is a Patient Navigation Adviser at Sunnybrook Health Sciences Centre. He is a former Health Editor of The Globe and Mail. Find him on Twitter @epaultaylor and online at Sunnybrook’s Your Health Matters. https://www.theglobeandmail.com/life/health-and-fitness/article-can-you-use-cannabis-to-calm-dementia/ Bongme
  16. Hi How can nanomedicine be applied to cannabis? Imagine a world in which a tiny nanorobot could deliver a specific cannabinoid directly to your endocannabinoid (ECS) receptors. The nanorobot would be thousands of times smaller than the breadth of a human hair and could carry its small cargo inside a single droplet of liquid to deliver it directly to a target cell such as a cancer cell. Sound far-fetched? It may be closer than you think, because researchers are making great strides in the fascinating field of nanomedicine. The cannabis plant contains an amazing group of cannabinoids, terpenes, and flavonoids, and scientists are only beginning to unlock the complex pharmacology and potential of these compounds. Combined with nanomedicine, cannabis has even more potential to treat disease and provide overall health benefits for people. What is nanomedicine? Scientists can manipulate substances on an atomic scale, in the range of 1-100 nanometers, or one thousand times thinner than a sheet of paper. According to the US Nanotechnology Initiative, substances on the nanoscale have very different properties than bulk substances do—unique properties like better electrical conductance, higher strength, and different magnetic properties, light reflection, or chemical reactivity. Nanotechnology can be performed on solids, liquids, or gases to unlock these unique phenomena. For these reason, nanotechnology applications in medicine offer exciting promise and possibilities, especially when applied to cannabis compounds. Many nanotechnology applications are already in use—computer circuits made from carbon nanotubes allow for far greater computing power, and nanoparticles are already being used in pharmaceuticals to improve absorption. Researchers work on all kinds of aspects of nanotechnology, such as finding the best substance for nanoparticles, the best shape for a nanoparticle for a specific delivery, and the best transfer mechanisms for specific drugs. Nanoparticles can generate heat, deliver stem cells, be radioactive or metallic, and so much more. While many applications are still only imagined by scientists, at its full potential, nanotechnology could be the next medical revolution, vastly changing how diseases are detected and treated. Drug delivery One of the best applications of nanomedicine is in the area of drug delivery, whereby nanoparticles deliver substances directly to specific cells, like diseased cancer cells. Researchers can engineer nanoparticles to be attracted to a diseased cell and limit the ability to bind with and therefore damage healthy cells. Scientists at MIT and other institutions have successfully used specific nanoparticles to deliver drugs to tumors. Even more interesting is that nanoparticles are developed to work together—while one locates a tumor, another can use the signal from the first to effectively carry the drug to its intended target. In one interesting application, scientists have created a nanoparticle that looks for hydrogen peroxide present in inflamed tissue, then it releases a drug in that environment to target heart disease. Cannabinoids and nanotechnology There is great promise that nanotechnology and cannabinoids can make an impact on diseases like cancer, multiple sclerosis, Parkinson’s, diabetes, and a wide range of serious inflammatory diseases. Nanotechnology can help identify a disease at an early stage, perhaps even when a single cell has gone awry, and then deliver a targeted cannabinoid to correct a cell’s behavior, thus stopping the disease in its tracks. It may even be possible for a nanorobot to target a specific endocannabinoid receptor to shut down the entire inflammatory process for the betterment of a patient. Cannabinoid nanodelivery systems have entered the research mainstream, with scientists working on biologically engineered cannabinoids and other nanoparticles to be transported to cells, and by creating nanocarrier transport substances out of metallics or other substances. Delivery system research also touches on improving bioavailability—the rate at which the active substance of a drug enters the bloodstream—as well as improving the physical stability of nanoparticles and optimizing routes of administration, including injection, pills, or sublingual drops. A nanotechnology-based targeted drug delivery system can be formulated to deliver cannabinoids directly to endocannabinoid receptors, where the magic happens. Cannabinoids can be packed inside a nanoparticle and carried to its intended target without degradation and with a controlled release. For example, nanoemulsions are already used in the food industry to deliver probiotics or other bioactive ingredients in a very controlled release. These nanoemulsions use a combination of two liquids that don’t normally combine—such as oil and water—to serve as a barrier to chemical degradation for the cannabinoid while on its journey through the body. Other encapsulation methods can help with potency issues by increasing absorption, they can help decrease side effects, and they can help cover a substance’s bitter taste. Specific cannabis strains could even have tailored therapeutic profiles, and cannabinoids could be bioengineered to produce enhanced effects. Scientists envision a superclass of cannabinoid nanocarriers that have potential to treat a wide array of endocannabinoid insufficiency issues and thus a wide variety of diseases. In one example, researchers are looking at novel ways to deliver substances across the difficult blood-brain barrier. This barrier is the body’s built-in defense mechanism to protect the brain, so the ability to transport substances across it directly affects a treatment’s efficacy. To this end, scientists are engineering lipid nanocapsules decorated with minute cannabinoids like CBD as novel therapies for diseases of the central nervous system. What does the future hold? Nanotechnology has already transformed drug delivery in profound ways, and cannabinoid delivery is part of this exciting future. There are challenges, of course. Cannabinoids quickly degrade in water and are susceptible to other kinds of degradation, and that presents delivery issues. More recent discoveries, including the decoding of the cannabis genome, discovery of the main CB1R and CB2R receptors within the human endocannabinoid system (ECS), and discovery of other receptors, are also foundational efforts that contribute to cannabinoid nanotechnology. The latest research shows great progress in the formulation of targeted cannabinoid-nanocarrier delivery systems, and as such may provide key therapies particularly for central nervous system disorders. As scientists continue to make improvements in both bio-efficacy and bioavailability, cannabis nanotechnology represents an exciting and brave new world. https://www.leafly.com/news/science-tech/how-can-nanomedicine-be-applied-to-cannabis Bongme
  17. Hi All, Looking for some advice on the supplied photos - the seedlings don’t look great, a little shrivelled and some loss of colour. 100w LED on min setting 24-26c 70-80% rh Only using clonex as a foliar feed atm
  18. hi New “Cannabis For Dementia” Podcast Launches If the stigma surrounding cannabis wasn’t bad enough, compound it with one of the most stigmatized medical conditions of all – dementia. Surprisingly, what emerges is a very promising treatment for the symptoms of this devastating illness. Dementia and its associated symptoms of aggression, agitation and sleeplessness are notoriously difficult to treat using pharmaceutical drugs. But despite their poor outcomes and severe and even-life-threatening side-effects, these drugs are typically the only line of care offered these patients. Yet some studies, supported by increasing clinical experience and anecdotal accounts, indicate that cannabis can in fact be used safely and effectively to reduce the symptoms that torment dementia patients, their families and their caregivers. The challenge is how to get it to them. There are myriad reasons why the vast majority of physicians in the United States will not recommend cannabis in general, and for treating dementia in particular. These include a lack of solid research regarding its safety and efficacy, its Schedule-1 classification, and fear of endangering federal funding to their institutions, among others. This leaves many families, desperate to alleviate their loved-one’s suffering, to simply offer cannabis to them under the radar. Such was the experience of Chela and Dave Coennen. After Chela’s mother developed Alzheimer’s disease and dementia and could no longer live alone, she moved into the couple’s home. Already a demanding personality, dementia exacerbated her aggressive behavior. But one evening when Chela shared a joint with her mother, she immediately became communicative, sociable and cooperative. Ultimately, Chela’s mother lived out her days in skilled-care facilities. But the family’s experience with cannabis left a lasting impression, and Chela and Dave decided to become advocates to support others in similar situations. On May 1, they launched the “Cannabis Helps Dementia” podcast, to share their experience and “connect with experts in the medical field and with other caregivers exploring the science and telling the stories of how cannabis can be the most effective and safest of any medicine being used for people living with dementia today.” The first three episodes can now be downloaded on iTunes, Spotify, Google Podcast and more thru Anchor.FM. Especially recommended is Episode 3, with particularly articulate input from Dr. Jeffrey Hergenrather, who is one of the most experienced clinicians working with cannabis in the country, if not the world. Dr. Hergenrather, who is one of the founders and former head of the Society of Cannabis Clinicians, describes how, working with the staff and residents of assisted living facilities in Northern California, they were able to help patients find relief from dementia symptoms and wean off other drugs using cannabis. The podcast also invites those who have used cannabis as they care for patients with dementia to share their stories. Hopefully, this will create a supportive resource and forum where these real-life experiences can be brought to light. The experience of COVID-19 is already dramatically impacting the nursing home model. With home-care for the elderly becoming an ever more realistic option, every opportunity we have to help dementia patients live peacefully, including medical cannabis, should be on the table. https://www.forbes.com/sites/abbierosner/2020/05/04/new-cannabis-for-dementia-podcast-launches/#3aef03e22bd6 Bongme
  19. Hi Should You Quit Smoking Cannabis During the Coronavirus Pandemic? Best to see it from link with tweets and all... https://www.ccn.com/should-you-quit-smoking-cannabis-during-the-coronavirus-pandemic/ Bongme
  20. hi Medical Cannabis and Arthritis – Could it Help? As a whole new demographic of patients begin to embrace the potential health benefits of cannabis, scientific studies and trials are becoming ever more common. From chronic pain and chemotherapy-induced nausea to spasticity in Multiple Sclerosis, cannabis is now considered as a treatment option in an increasing number of jurisdictions. But, can medical cannabis help to treat Arthritis? What is Arthritis? Arthritis is a common condition that usually causes pain and inflammation in joints. It is estimated that Arthritis, or similar conditions, currently affects around 10 million people in the UK alone. Although the condition may often be associated with older people, it can actually affect people of all ages. The Two Most Common Forms of Arthritis are Osteoarthritis and Rheumatoid Arthritis… Osteoarthritis is the most common form of the condition and is thought to affect the cartilage lining of the joint. This can make movement difficult and painful. In contrast, Rheumatoid Arthritis, pain and swelling are caused by the immune system attacking affected joints. Arthritis can also cause redness to the skin around the affected area, as well as muscle wasting. Medical Cannabis and Arthritis Currently, there is no cure for Arthritis, with the majority of treatment options aiming to simply alleviate symptoms of the condition. For example, pain medications such as opioids, as well as physiotherapy are often considered to relieve pain and encourage movement. However, a growing number of patients are becoming reluctant to take prescription painkillers, as they can come with negative side effects and are often highly addictive. Cannabis has been used for thousands of years for its anti-inflammatory properties, which can help to soothe pain. Is There Any Evidence? Anecdotal evidence for the potential of medical cannabis in Arthritis treatment has circulated for years. Many patients have claimed that using cannabis in some form has helped with pain and inflammation caused by the condition. However, an increasing number of clinical studies are now focusing on the treatment. The cannabinoids found within the cannabis plant are thought to interact with our body’s Endocannabinoid system. This system is made up of a collection of CB1 and CB2 receptors which, when activated, can monitor a number of physiological processes. One study, published in the journal Rheumatology, found that CB2 receptors were found in unusually high levels in the joints of people with Rheumatoid Arthritis. The researchers concluded that these receptors could potentially be an effective treatment target for this form of Arthritis. In addition, a number of animal studies have yielded positive results when assessing the effects of cannabis compounds in treating Arthritis. For example, one study assessed the efficacy of cannabidiol (CBD) in Arthritic rats. The researchers found that the cannabinoid demonstrated a promising therapeutic treatment option for Osteoarthritis. Is Medical Cannabis Legal for Arthritis? Medical cannabis has been legalised in a number of countries around the world. In the USA, a number of states allow medical cannabis prescriptions to be provided for Arthritic conditions. In some countries, including the UK, medical cannabis products are prescribed at the discretion of specialist doctors. Currently, patients may be offered a prescription for medical cannabis, often through private clinics, if other treatment options have not offered satisfactory relief. https://canex.co.uk/medical-cannabis-and-arthritis-could-it-help/ Bongme
  21. Hi Cannabis, neuropsychiatry and education with Dr Ilya Reznik Dr Ilya Reznik discusses the use of cannabinoid-based medicines for neuropsychiatric disorders and the barriers to prescribing CBD. Dr Ilya Reznik has published many original papers (including controlled trials), reviews and case reports in leading peer reviewed journals in the fields of clinical psychiatry and neuropsychopharmacology. Dr Ilya Reznik’s current main interest is in the field of the medical use of cannabis and cannabinoids, especially for various neuropsychiatric illnesses, such as chronic pain syndrome, post-traumatic stress disorder (PTSD), OCD, Tourette syndrome, Parkinson’s and Alzheimer’s diseases. Dr Ilya Reznik also co-ordinates the activity of Israel National Forum/Association for Medical Cannabis Research and Treatment; and in 2013 was elected to the Board of Directors at the International Association for Cannabinoid Medicines (IACM). Medical Cannabis Network spoke to Dr Ilya Reznik in Dublin on the sidelines of the Europe Canna Expo, Europe’s premier event series dedicated to cannabinoids and medical cannabis, to discuss areas including the use of cannabinoid-based medicines for neuropsychiatric disorders and some of the barriers to prescribing. What are the most significant neuropsychiatric applications of medicinal cannabis? I am a specialist in cannabinoid medicine, and we are looking for the ways in which cannabis as a plant and its derivatives can influence human subjects with regard to helping them with a medical condition. As a neuropsychiatrist, I am interested in how cannabis can influence a neuropsychiatric condition such as epilepsy. As a medicine, cannabis’s most significant effects are neurological and psychiatric – although, of course, it can also be used to help treat pain, particularly for cancer patients. And cannabis and its derivatives are most widely used to help treat neuropsychiatric conditions like head trauma, post-traumatic stress disorder, Tourette syndrome, epilepsy; as well as neurodegenerative disorders like Alzheimer’s and Parkinson’s. What benefits has cannabis shown in the treatment of elderly patients? Most elderly patients are not being treated because they have a neurodegenerative disorder, but just because they are elderly; and so, within the natural course of their lives they have developed a particular problem such as diabetes, high blood pressure, and so on. Most also have experienced a lot of pain stemming from conditions such as arthritis. We therefore look at how we can help them in a general sense, and to do this I will typically look at three areas. The first area is recreational – whether people are taking cannabis recreationally. The second is medicinal – do they have an identifiable medical disorder? If so, we can decide how we are going to treat it. And the third is wellbeing. But the borders between each of these three areas are not absolute, and there is a lot of overlap from one to the next. For instance, we may be able to have an impact on a person’s wellbeing by treating their medical condition. Cannabis is a very unspecific substance; it has many different components and each one does something different in the endocannabinoid system of the human body. The variety is so large that we will probably never have conclusive studies. But we do know that when a person takes cannabis as a medicine, they can experience more than one effect. Because of this variety of effects, is there a clear need for a personalised medicine approach? Cannabinoid medicine is a prime model for personalised medicine. Sometimes industry doesn’t like that; they want to use the same molecules for everyone, and while that might work with regard to medicinal cannabis, it will also mean that some parts of the population won’t see a benefit. What are the key challenges currently facing doctors who wish to prescribe cannabis and its derivatives to their patients? It is important to look at the step before prescribing. The main challenge for cannabinoid medicine is the level of resistance within the community of doctors. For 80 years, clinicians have been taught to see cannabis as a dangerous narcotic drug. As such, we need to keep this traditional approach in mind; the largest resistance to cannabis is not on the part of lawmakers but the doctors. That is the biggest barrier to cannabis as a medicine at the moment – and that tends to be because doctors have not been educated on the benefits of the plant, and so we need a common movement, a bottom-up approach from doctors like me who take it upon themselves to get educated and to educate other doctors. But a top-down approach is also required, whereby cannabis is approved as a medicine – such as Sativex, which is FDA and EMA approved. Clinicians will, I believe, come to accept medicines such as Sativex because it has been approved. But it will take time. Should the endocannabinoid system be included in the education programmes for new clinicians? For the last 10 years, the textbooks being used in medical schools have not been changed, and these texts do not include a description of the endocannabinoid system. As such, we cannot even expect clinicians to be aware of it. Are there any side effects or safety issues with medical cannabis which patients may not know about? We should be aware of our abilities to enjoy or be harmed by the many different things we will encounter in our lives. For instance, we know not to cross the street without looking for traffic first or we may be hit by a car. Our safety there is our own responsibility. And the same should be true when we make the decision to use something like cannabis. I have prescribed cannabis to young women who suffered both pain, depression and PTSD: they were lucky enough to be granted the licence; and they benefited from the medicine and went on to have get married and then became pregnant, at which time the Israeli government asked us to stop prescribing them cannabis because they were pregnant. I am a member of our parliamentary committee for cannabis regulation and I asked the lawmakers not to stop their treatment, because if they did then it was highly likely that the patients would resort to sourcing cannabis on the black market; which will not only be funding crime but will also mean that the cannabis they are using will be of a low quality. I asked the government to make it so that the responsibility of the health of the unborn child rested with the parent. They could be told of the risks associated with continuing to take cannabis while pregnant, and so if they made the decision to continue to do so then the responsibility rested with them, and not with the doctors or the government. The same is true for children. We should not be able to say that children cannot access medicinal cannabis just because of their age when there are numerous patients, not least those with severe epilepsy, who can benefit considerably from taking CBD. The point here is that we need to weigh the consequences and the benefits, and not take a one size fits all approach. We need to look at things on a case-by-case basis. How should clinicians therefore educate themselves further in order to best support patients who may benefit from medical cannabis? This is a very interesting question. Many doctors don’t work with all the tools that they have available to them. They will tend to reach for the method or tool that has worked for them in the past and which they are familiar with. I consider cannabinoid-based medicine to be a complementary medicine: it is not a mainstream medicine and probably never will be. Currently, cannabinoid-based medicine is adjunctive; and so, the majority of patients that I have with PTSD continue their conventional medicine in addition to cannabis-based treatment, but others are able to stop taking that and take CBD instead. Doctors who would like to practise complementary medicine need to know how and when it can be used. Of course, some will not practise complementary medicine at all and will only use traditional methods and will therefore never learn about cannabinoid-based medicine; but others, like myself, will see it for what it is – potentially the best medicine that we have at our disposal – and we will prescribe it when we feel it will have a benefit. Then the remaining 80% or so of clinicians will take a middle position – they may become interested in it and they may also see it as a way of boosting their careers. We have a lot to do moving forwards, but I think we should realise that what we are doing now is a part of history; we are making history. In the future, when people look back on the history of cannabis as a medicine, they will remember conferences like the one we are at today as being integral in the changes that were made in the medical landscape. Dr Ilya Reznik Chief Physician Medical Institute for Forensic & Diagnostic Neuropsychiatry MaReNa Diagnostic and Consulting Centre https://www.healtheuropa.eu/cannabis-neuropsychiatry-education-dr-ilya-reznik/99248/ Bongme
  22. Hi Cannabis users encouraged to take a break over lockdown period due to COVID-19 health risks Stoners are being told to ease up on the weed over the duration of the COVID-19 pandemic, with scientists saying the health risks are significant. Dr Marta Rychert, a senior research officer at Massey University's SHORE and Whariki Research Centre says around five percent of New Zealand's population uses cannabis as medication. "People who self-medicate with cannabis are the most vulnerable in the terms of COVID-19," she said in a statement on Tuesday. "They are older than recreational users and often suffer from multiple health problems." A recent survey by SHORE showed the most popular way to use marijuana was to smoke it. "Smoking presents unique risks in the context of COVID-19 due to the impacts on lung function." People who self medicate using oils or tinctures will not suffer the same ill effects. Dr Rychert says people who use cannabis for fun need to be careful too. The usual practices of recreational marijuana use present a serious risk during the pandemic. "[They] need to pay attention to the hygienic practices they normally may not think about," she said. "This is because sharing of cannabis joints, bongs or vapes, also creates risks for COVID-19 transmission." Buying drugs also presents a significant health risk, says SHORE and Whariki associate professor Chris Wilkins. " One drug dealer may have face-to-face contact with many buyers involving exchanges of cash and drugs that have the potential to transmit the disease," he said on Tuesday. "We are in the harvest months for cannabis and growers may seek to travel to crops and also sell cannabis to many customers, with potential for transmission." The NZ Drug Foundation has advised heavy drug users to use the lockdown period as a chance to take a break but has warned people to stay wary of the signs of withdrawal which can range from disorientation to trouble sleeping. https://www.newshub.co.nz/home/new-zealand/2020/03/cannabis-users-encouraged-to-take-a-break-over-lockdown-period-due-to-covid-19-health-risks.html Bongme
  23. hi Does Cannabis Use Affect Exercise Levels in Adolescents? Many studies have found that the majority of adolescents around the world do not get the 60 minutes of exercise per day, recommended by the World Health Organisation (WHO). However, a recent study shows that those that use cannabis may be even less likely to meet this recommendation. Although most past studies have focussed solely on US populations, this is not a new area of research. In this study, researchers focussed on low and middle-income countries where cannabis use appears to be on the rise. How was Cannabis Use Measured? The data used in the study was gathered through the use of Global school-based student health surveys. The survey, designed to assess the risk and protective factors of major diseases. was developed by WHO and the US Centre for Disease Control and was distributed in 21 countries around the world. A total of 89,777 students, aged between 12-15, completed the survey. The 21 countries assessed in the study were categorised as either low-income, lower middle-income, or upper middle-income. In order to assess cannabis use in participants, researchers asked: “During the past 30 days (or during your life), how many times have you used marijuana?” Responses to the survey revealed that 1% (approximately 897) of participants had used marijuana in the past. In comparison, 2.9% (approximately 2,604) of respondents claimed to currently use marijuana. Measuring Cannabis Use Against Excercise In order to assess levels of exercise among participants, researchers asked about their physical activity over the last seven days. Participants who reported at least 60 minutes of physical activity per day were considered to be getting enough exercise. The data showed that only a small proportion of respondents (16.6%) were getting sufficient exercise in line with WHO recommendations. However, the percentage of adolescents who got enough exercise was even lower among those who had used marijuana. The data showed that only 7.3% of respondents that had used marijuana in the past, were getting enough exercise. This rate fell even lower among students who reported current use of marijuana (6.9%). What is the Relationship Between Cannabis and Exercise? While the relationship between cannabis use and exercise has been touched upon in the past, researchers are yet to draw definitive parallels between the two factors. Researchers have speculated that cannabis use may lead to a lack of motivation, caused by the effect cannabis has on dopamine production and reward sensitivity. Cannabis use may also increase feelings of lethargy, meaning that users are less likely to exercise. Although this research offers an interesting insight into the effects of cannabis use on physical activity, it may not reveal the full picture. For example, many young people may be unwilling to admit to cannabis use, particularly in a school survey. This method of research is also unable to tell us what kind, strength, and quality of cannabis is consumed. Furthermore, it is unclear that cannabis use causes a lowered desire to exercise. It could equally be speculated that students who exercise less may be more likely to partake in cannabis use. However, this study does echo the findings of past studies in the same area. Namely, that cannabis use may affect exercise levels. https://canex.co.uk/does-cannabis-effect-exercise-levels-in-adolescents/ Bongme
  24. hi Cannabis and coronavirus: Here’s what you need to know The global concern over the coronavirus known as COVID-19 has many people taking precautions against contracting the virus. Here’s what we know about cannabis and this novel coronavirus. How cannabis users can stay healthy around coronavirus Stop sharing joints, blunts, and bongs while coronavirus is spreading The puff-and-pass customs surrounding cannabis are among the greatest pleasures of the plant. But passing around a joint is is a good way to spread any virus, including COVID-19. For now, stick to your own supply and offer a friendly elbow bump. Wash your hands frequently We can’t emphasize this enough. Thorough handwashing really, really, really does help prevent transmission of coronavirus, as well as other ailments. Before you sit down for a session or dig into some munchies, make sure to wash your hands for a count of 20 seconds. That’s as long as it takes to sing “Happy Birthday to You”—or the first chorus of Sublime’s “Smoke Two Joints.” Just saying. Don’t buy into unproven coronavirus remedies Given the general hype around CBD, expect to hear outlandish claims about its effect on coronavirus, most likely spread via social media. These claims are not true. There is no solid research on CBD and coronavirus. Be cautious with cannabis around COVID-19 Smoking weed when you’re down with a virus: Not such a great idea. Leafly’s article Cannabis for colds and flu? Here’s what the experts say has a lot of helpful advice about integrating cannabis (or not) into the treatment and recovery from a normal flu. Yes, THC and CBD have pain-relieving, sleep-inducing, and anti-inflammatory properties. But inhaling hot smoke is the last thing your lungs need when fighting a cold or flu. Do your research before medicating. Take precautions about physical contact with others Stop shaking hands. A wave or friendly verbal greeting helps everyone. You don’t need to lock yourself in a panic room, but do consider your interactions with other people and with public surfaces when out and about. Leave the face masks for ill patients and healthcare providers The CDC and other health agencies are clear on this: Masks are meant to prevent already infected patients from spreading the virus, and to protect healthcare professionals working in high-risk environments. Frequent handwashing is far more effective than wearing a mask. Be aware of COVID-19 symptoms Don’t jam up the emergency room if it’s just a common cold, but get yourself tested if you fit the criteria for COVID-19 symptoms. Those include: Fever Cough Shortness of breath Have been in contact with a COVID-19 patient, or traveled recently to an area with ongoing spread. Note: The definition of “area with ongoing spread” changes practically by the hour, and this item on the symptom list is becoming less important as the virus is recognized as extant in local communities. Have a self-quarantine plan At this point we’re talking about a spectrum, from choosing a work-at-home option (if you’re fortunate enough to have that choice) to a full-on home quarantine. The CDC has a page of recommendations for those who stay home with a suspected case of COVID-19. Are bong condoms really a thing? Absolutely! Get yourself one of these fun devices. One of our in-house experts suggests this $8 silicone rubber mouthpiece from Dabbing Warehouse, an embarrassingly shaped device that fits over the mouth of a bong or dab rig for hygienic inhaling. Others prefer the $15.99 silicone MouthPeace from Mooselabs, which uses activated carbon filters. Jay the Cannabis Explorer reviews it in the video below: Another suggestion: Pax Era mouthpiece covers can be had for $4.30 a pop from Delta 3D Studios. Use an X-Acto knife to cut a hole in the closed end and you’ve got yourself a personal lip caddy. Note: Most viral transmission happens via the hands, so while you’re being so clever with your lips you should watch your fingers, which are holding a bong or vape that many others have just recently held as well. Just saying. Will this affect cannabis product supplies? Because all legal cannabis products are produced within the state in which they’re sold, industry experts aren’t expecting a shortage of actual cannabis due to import slowdowns. That’s not to say there won’t be shortages or supply interruptions in certain products. Most vape batteries and wholesale vape cartridges are manufactured in China. Those supply chains have already seen slowdowns and interruptions due to quarantines impacting the Chinese manufacturing sector. The US imports about 30 million Chinese vape pens and cartridges every month. Most shipments stopped due to the annual Chinese New Year shutdown in mid-January and haven’t fully resumed due to the coronavirus. “A supply pinch is coming in weeks and will persist for months,” says Dan Fung, CEO of American Made Vapes. “Prices will rise. Shortages of packaging and vape pens could occur.” Much of the packaging materials utilized by cannabis companies is also manufactured in China, so a slowdown in those materials may result in a slowdown in stateside production. The development of new cannabis-related products may be slowed as well, as designers and manufacturers can’t rely on a steady supply of wholesale products and materials from China right now. Will this affect 4/20 events? The likely answer is yes. Organizers of 4/20 celebrations, which are now less than six weeks away, are already considering how a wider outbreak of COVID-19 could impact their events. One cannabis store manager told Leafly he was putting a food truck ordered for 4/20 on hold because of health concerns. 4/20 festivals were already changing and evolving due to the expansion of legalization. The coronavirus outbreak may further accelerate that change in ways that are hard to predict right now. What about legalization campaigns? If COVID-19 spreads to more American cities, we may see more cancellations of larger events, gatherings, and festivals. Larger-scale shopping malls and commercial districts may see a downturn in pedestrian traffic. That may affect the ability of signature gatherers to bank enough names to qualify legalization initiatives by a given deadline. Leafly’s Election 2020 page has a full rundown of all the state legalization campaigns currently aiming at the November 2020 ballot. https://www.leafly.com/news/health/cannabis-coronavirus-covid-19-facts Vid Bongme
  25. Hi CBD Toothpaste? Colgate Sinks its Teeth into the CBD Industry nternational personal care giant Colgate Palmolive has announced that it is set to acquire CBD oral care company, Hello Products. It is the most recent in a wave of established health brands entering the CBD space through acquisition. Hello Products has successfully positioned itself in the natural health and beauty space since it was founded in 2012. The company’s product line includes CBD-infused toothpaste and mouth rinse, as well as toothbrushes and lip balms. It is currently stocked in over 44,000 US retail locations, including over 1,000 Ulta Beauty stores. Colgate’s President and CEO stated: “We have great respect for the Hello team and their impressive product line, and value the strong connection they have made with younger consumers.” Hello Products launched its CBD range in February, following the success of its core range of all-natural products. They also offer a range of products containing hemp seed oil and hemp extract. CBD is one of the most prominent of the many cannabinoids found in the cannabis plant. Unlike the other well-known cannabinoid, THC, it does not cause a high when consumed. However, it has been found to have a number of potential benefits to our health through its interaction with our body’s endocannabinoid system. The most quoted of CBD’s benefits are its potential as an anti-inflammatory and anti-oxidant. It is also believed to be effective at reducing stress and anxiety and promoting sleep. Prohibition Partners has predicted that the global CBD health and beauty industry could be worth up to $959 million by 2024. That’s up from an estimated $710 million in 2018. Many large health and beauty companies, including L’oreal and Estee Lauder, have already made moves to enter the CBD industry through the acquisition of smaller CBD companies. It remains unclear whether Colgate is planning to distribute Hello Products globally. However, the move represents a major move for CBD into the oral hygiene space. Could CBD toothpaste be the next big thing? https://canex.co.uk/cbd-toothpaste-colgate-sinks-its-teeth-into-the-cbd-industry/ Bongme